Strauß, Arne

[["dc.bibliographiccitation.firstpage","640"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","BJU International"],["dc.bibliographiccitation.lastpage","644"],["dc.bibliographiccitation.volume","109"],["dc.contributor.author","Schaefer, Inga-Marie"],["dc.contributor.author","Seeliger, Stephan"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Fuezesi, Laszlo"],["dc.contributor.author","Ringert, Rolf-Hermann"],["dc.contributor.author","Loertzer, Hagen"],["dc.date.accessioned","2018-11-07T09:13:52Z"],["dc.date.available","2018-11-07T09:13:52Z"],["dc.date.issued","2012"],["dc.identifier.doi","10.1111/j.1464-410X.2011.10916.x"],["dc.identifier.isi","000299945100030"],["dc.identifier.pmid","22313503"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/27265"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1464-4096"],["dc.title","Surgery Illustrated - Focus on Details A three-step technique for umbilicoplasty in a patent urachus"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","715"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","International braz j urol"],["dc.bibliographiccitation.lastpage","722"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Seseke, Sandra"],["dc.contributor.author","Bierwirth, Silke"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Ringert, Rolf-Hermann"],["dc.contributor.author","Seseke, Florian"],["dc.date.accessioned","2018-11-07T11:09:29Z"],["dc.date.available","2018-11-07T11:09:29Z"],["dc.date.issued","2008"],["dc.description.abstract","Purpose. The optimal management of patients with clinical stage I non-seminomatous germ cell testicular cancer (NSGCT I) was considered controversial until the European Germ Cell Cancer Consensus Group determined unambiguous treatment strategies In order to assess the long-term outcome we evaluated the data of patients with NSGCT I. Materials and Methods In a retrospective evaluation, we included 52 patients with a mean age of 26 years (range 15-58) who were treated with different modalities at our department between 1989 and 2003. Mean follow-up was 5 9 years (range 2-14 years) After orchiectomy, 39 patients were treated with chemotherapy, 7 patients underwent retroperitoneal lymph node dissection and 6 men were managed using a surveillance strategy. Survival, recurrence rate and time of recurrence were evaluated. The histological staging and treatment modality was related to the relapse. Results Tumor specific overall mortality was 3.8%. The mortality and relapse rate of the surveillance strategy, retroperitoneal lymph node dissection and chemotherapy was 16 7% / 50%, 14.3% / 14 3% and 0% / 2 5% respectively. All relapsed patients in the surveillance group as well as in the RPLND group had at least one risk factor for developing metastatic disease Conclusions Following the European consensus on diagnosis and treatment of germ cell cancer in patients with NSGCT Stage I any treatment decision must be individually related to the patient according to prognostic factors and care capacity of the treating centre. In case of doubt, adjuvant chemotherapy should be the treatment of choice, as it provides the lowest risk of relapse or tumor related death."],["dc.identifier.isi","000207705700013"],["dc.identifier.pmid","19111076"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/53018"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Brazilian Soc Urol"],["dc.relation.issn","1677-5538"],["dc.title","Long-term Clinical Outcome in Patients with Stage-I Nonseminomatous Germ Cell Cancer. A Critical Review of Own Treatment Modalities in a Retrospective Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2626"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Molecular Cancer Therapeutics"],["dc.bibliographiccitation.lastpage","2633"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Stettner, Mark"],["dc.contributor.author","Kaulfuss, Silke"],["dc.contributor.author","Burfeind, Peter"],["dc.contributor.author","Schweyer, Stefan"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Ringert, Rolf-Hermann"],["dc.contributor.author","Thelen, Paul"],["dc.date.accessioned","2018-11-07T10:58:18Z"],["dc.date.available","2018-11-07T10:58:18Z"],["dc.date.issued","2007"],["dc.description.abstract","In the prostate, estrogen receptor beta (ER beta), the preferred receptor for phytoestrogens, has features of a tumor suppressor. To investigate the mechanisms underlying the beneficial effects on prostate cancer of histone deacetylase inhibitor valproic acid (VPA) and phytoestrogen tectorigenin, we analyzed the expression of ER after tectorigenin or VPA treatment. For further functional analysis, we knocked down ER beta expression by RNA interference. LNCaP prostate cancer cells were treated with 5 mmol/L VPA or 100 mu mol/L tectorigenin and transfected with small interfering RNA (siRNA) against ER beta. Control transfections were done with luciferase (LUC) siRNA. Expression of ER beta was assessed by Western blot. mRNA expression was quantitated by real-time reverse transcription-PCR. Expression of ER beta mRNA and protein markedly increased after VPA or tectorigenin treatment. When ER beta was knocked down by siRNA, the expression of prostate-derived Ets factor, prostate-specific antigen, prostate cancer-specific indicator gene DD3(PCA3), insulin-like growth factor-1 receptor, the catalytic subunit of the telomerase, and ER beta was up-regulated and the tectorigenin effects were abrogated. ER beta levels were diminished in prostate cancer and loss of ER beta was associated with proliferation. Here, we show that siRNA-mediated knockdown of ER beta increases the expression of genes highly relevant to tumor cell proliferation. In addition, we show that one prominent result of treatment with VPA or tectorigenin is the up-regulation of ER beta resulting in antiproliferative effects. Thus, these drugs, by restoring the regulatory function of ER in tumor cells, could become useful in the intervention of prostate cancer."],["dc.identifier.doi","10.1158/1535-7163.MCT-07-0197"],["dc.identifier.isi","000250252100003"],["dc.identifier.pmid","17913855"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50445"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Assoc Cancer Research"],["dc.relation.issn","1535-7163"],["dc.title","The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Loertzer, Hagen"],["dc.contributor.author","Ringert, Rolf-Hermann"],["dc.contributor.author","Thelen, Paul"],["dc.date.accessioned","2018-11-07T09:10:22Z"],["dc.date.available","2018-11-07T09:10:22Z"],["dc.date.issued","2012"],["dc.identifier.isi","000318009803054"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26474"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.conference","48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)"],["dc.relation.eventlocation","Chicago, IL"],["dc.relation.issn","0732-183X"],["dc.title","Antitumor effects of zoledronic acid in combination with histone deacetylase inhibitor valproic acid"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Thelen, Paul"],["dc.contributor.author","Ringert, Rolf-Hermann"],["dc.contributor.author","Strauss, Arne"],["dc.date.accessioned","2018-11-07T09:10:23Z"],["dc.date.available","2018-11-07T09:10:23Z"],["dc.date.issued","2012"],["dc.identifier.isi","000318009802848"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26477"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.conference","48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)"],["dc.relation.eventlocation","Chicago, IL"],["dc.relation.issn","0732-183X"],["dc.title","Histone deacetylase inhibitor (HDACi) LBH589 interference with androgen receptor expression transcriptional activity in prostate cancer cells."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]